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Revisiting Hyperkalemia Guidelines 
Rebuttal  
 
Javed Butler, Shilpa Vijayakumar, and Bertram Pitt 
 
“And don't criticize 
What you can't understand” 
The Times They Are A-Changin, Bob Dylan 
 
We read the rebuttal to our viewpoint by Bayes-Genis and colleagues with great interest. We agree 
on the facts. The issue at hand is what action to take given the data available today. Bayes-Genis et al 
give four reasons as to why there is no need to change current guidelines. We respectfully argue that 
these arguments, while scholarly, do not obviate the need for reassessing guidelines. 
1. We agree that revising guidelines may risk sub-optimal prescription of renin-angiotensin-
aldosterone system inhibitors (RAASi). We also agree that a large part of RAASi suboptimal use is 
driven by high-risk patient characteristics for adverse effects. But isn’t this a reason to revise 
guidelines to safeguard patients at high-risk for adverse effect to a given therapy?  
2. We agree that the causal relationship between the U-shape serum potassium concentration and 
outcomes is not well understood. Obviously hypokalemia should be avoided, but that is not a 
reason to not revise hyperkalemia guidelines. We explicitly state that the risk association 
between potassium levels and adverse outcomes is a combination of patient phenotype and 
comorbidity burden, lack of optimal medical therapy due to hyperkalemia, and risk directly 
attributable to hyperkalemia. We need to elucidate these associations and their causal 
relationships better, but should we not be focus on patient safety while such research is being 
conducted when in the meantime study after study is raising concerns, granted they are 
observational?  
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3. We agree with the erudite recap of the effect of valsartan-sacubitril on risk of hyperkalemia. Less 
risk of hyperkalemia with this drug is a welcome addition to heart failure therapies that may help 
optimization of mineralocorticoid receptor antagonists (MRA) use. However, this issue is not 
relevant to our concern, i.e. how to proceed once you do develop hyperkalemia. 
4. We completely agree that we need outcomes studies with novel potassium binders, however, 
while we await such data, how do we address patient risk today? 
Clinicians face management conundrums daily where there are risks in both action and inaction, and 
the guide in such scenarios is to lean in favor of patient safety. If serum potassium concentration 
between 5.0-5.5 mmol/l was not of clinical concern, then it is curious to note that uniformly all clinical 
trials in heart failure with RASSi uniformly excluded patients with baseline serum potassium 
concentration of >5.0 mmol/l. We suggest that patients not on an MRA maintain their serum 
potassium to < 5.0 mmol/l. We also appreciate that patients who develop hyperkalemia on MRA 
therapy nevertheless benefit from MRA, and therefore until further prospective data with potassium 
binders become available, MRA perhaps should be continued for patient with serum potassium 
concentration up to 5.5 mmol/l (1, 2). However, even in these studies, while there was a relative risk 
reduction, the risk for adverse outcomes was higher in those with higher serum potassium 
concentration even in the presence of MRA therapy. Also, the trajectory of potassium changes once 
hyperkalemia developed in given individuals is not known from these studies.  
 
We appreciate the potential for sub-optimal medical therapy due to hyperkalemia and urge 
investigators and sponsors to conduct clinical trials with potassium binders to guide optimization of 
therapy to reduce cardiovascular risk compared to current approaches as soon as possible. However, 
until we better understand the relationship between elevated serum potassium levels and outcomes, 
we recommend erring on the side of caution.   
 
Primum non nocere! 
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